eMS News

In the latest issue of InforMS, we explore what we know about the potential benefits and harms of the existing therapies for multiple sclerosis, how we think today about the…

While there’s no MS cure, new drugs have made the feared disease recedeDenver Post

Rocky Mountain Multiple Sclerosis Center’s Medical Director, Dr. Tim Vollmer, Selected as Principal Investigator for NeuroNEXT Clinical Site

Renowned MS expert to speak: Advances in treament moving quickly

Novartis’s Gilenya Loses Market Share After Safety Review“If they have any history of any kind of cardiac disease, we won’t consider the drug,” Vollmer said in a telephone interview. “For…

Introduction to MS and the MS Center, an interview with MS Center Executive Director, Karen Wenzel and Dr. Vollmer. NoMoreRack.com raises $7,862 for The Rocky Mountain MS Center during MS…

With the recent announcement confirming the increased number of PML cases, other information has become available as well. Of the 24 cases, two-thirds have been in Europe and one-third in…

Fingolimod is an oral agent that is now being researched in three Phase III trials. This is the first of a new class of potential MS medications known as “S1P…